Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Children's Oncology Group
80 participants
Jun 19, 2017
INTERVENTIONAL
Conditions
Summary
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Given Asparaginase Erwinia chrysanthemi
Undergo blood sample collection
Undergo a bone marrow aspiration and biopsy
Given IV
Given IV
Given IV or SC
Undergo imaging
Given IV
Given PO or IV
Undergo lumbar puncture
Given IT
Given IV or IM
Given IV
Locations(157)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02981628